HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07546929
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Housey Healthcare ULC
- Registry
-
NCT07546929
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07546929. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-03 (actual); primary completion 2026-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HP-211
- Intervention (Drug)
- Placebo
- Lead sponsor
- Housey Healthcare ULC
Record details
- Record id
cardio:ct-nct07546929- Content hash
f4da427df58dda5067c288549e58e2830b2d5e368e6923e449e6337c5c4919d0